# Cytokinetics (CYTK) — Earnings

CYTK · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cytk/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$1.50 |
| EPS estimate | −$1.63 |
| EPS surprise | +7.87% |
| Revenue surprise | +62.75% |
| Revenue | $28.6M |
| Revenue estimate | $17.6M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/68cc5f8b-2548-a359-3f0e-2497763ba8cd.html) |

Cytokinetics reported Q2 2026 results on August 6, 2026. The company posted a loss of $1.50 per share, narrower than the $1.63 loss analysts expected, which the source records as a 7.87% beat. Revenue was $28.6 million against a $17.6 million consensus, a 62.75% beat. Compared with Q2 2025, the loss per share widened from $1.12, and revenue was lower than the $66.8 million reported a year earlier.

Cytokinetics reported a loss in every one of the 20 quarters in the table. Annual losses per share were $4.25 in 2022, $5.45 in 2023, $5.26 in 2024 and $6.53 in 2025. The first half of 2026 adds up to a loss of $3.17. Revenue has been small and irregular, ranging from $249,000 in Q2 2024 to $89.0 million in Q2 2022. The last three quarters show $17.8 million, $19.4 million and $28.6 million. Cytokinetics beat the EPS estimate six times over the last 20 quarters and missed 14 times.

Cytokinetics reported Q3 between November 2 and November 7 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue keeps rising and how the loss compares.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$1.63 | −$1.50 | 7.87% | $17.6M | $28.6M |
| Q1 2026 | May 5, 2026 | −$1.65 | −$1.67 | -1.07% | $8.5M | $19.4M |
| Q4 2025 | Feb 24, 2026 | −$1.56 | −$1.50 | 4.12% | $6.9M | $17.8M |
| Q3 2025 | Nov 5, 2025 | −$1.57 | −$2.55 | -62.36% | $6.0M | $1.9M |
| Q2 2025 | Aug 7, 2025 | −$1.43 | −$1.12 | 21.66% | $2.1M | $66.8M |
| Q1 2025 | May 6, 2025 | −$1.37 | −$1.36 | 0.69% | $3.4M | $1.6M |
| Q4 2024 | Feb 27, 2025 | −$1.19 | −$1.26 | -5.62% | $1.7M | $16.9M |
| Q3 2024 | Nov 7, 2024 | −$1.23 | −$1.36 | -10.16% | $1.2M | $463,000.00 |
| Q2 2024 | Aug 8, 2024 | −$1.06 | −$1.31 | -23.98% | $7.6M | $249,000.00 |
| Q1 2024 | May 8, 2024 | −$1.14 | −$1.33 | -16.29% | $912,849.00 | $835,000.00 |
| Q4 2023 | Feb 27, 2024 | −$0.96 | −$1.38 | -43.97% | $7.6M | $1.7M |
| Q3 2023 | Nov 2, 2023 | −$0.74 | −$1.35 | -81.74% | $20.2M | $378,000.00 |
| Q2 2023 | Aug 3, 2023 | −$1.14 | −$1.34 | -17.61% | $5.7M | $867,000.00 |
| Q1 2023 | May 4, 2023 | −$1.20 | −$1.38 | -15.06% | $2.1M | $4.6M |
| Q4 2022 | Mar 1, 2023 | −$1.21 | −$1.45 | -20.22% | $7.1M | $2.0M |
| Q3 2022 | Nov 3, 2022 | −$1.16 | −$1.52 | -30.61% | $3.5M | $2.5M |
| Q2 2022 | Aug 4, 2022 | −$1.03 | −$0.23 | 77.66% | $3.7M | $89.0M |
| Q1 2022 | May 4, 2022 | −$0.94 | −$1.05 | -11.28% | $4.3M | $1.1M |
| Q4 2021 | Feb 24, 2022 | −$0.85 | −$0.36 | 57.56% | $5.8M | $55.6M |
| Q3 2021 | Nov 3, 2021 | −$0.78 | −$0.95 | -22.42% | $6.0M | $5.4M |

## Frequently Asked Questions

### When did Cytokinetics (CYTK) last report earnings?

Cytokinetics last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did CYTK beat earnings estimates?

Yes. Cytokinetics reported EPS of −$1.50 for Q2 2026 against a −$1.63 estimate — a 7.87% beat.

### How much revenue did CYTK report last quarter?

Cytokinetics reported $28.6M in revenue for Q2 2026, against a consensus estimate of $17.6M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).